Myovant Sciences Return on Tangible Equity 2017-2022 | MYOV

Current and historical return on tangible equity values for Myovant Sciences (MYOV) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Myovant Sciences Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.21B $-0.47B 48.82%
2021-12-31 $-0.23B $-0.43B 58.13%
2021-09-30 $-0.24B $-0.38B 67.90%
2021-06-30 $-0.28B $-0.40B 92.73%
2021-03-31 $-0.26B $-0.35B 106.25%
2020-12-31 $-0.24B $-0.27B 133.89%
2020-09-30 $-0.25B $-0.20B 204.07%
2020-06-30 $-0.26B $-0.14B 370.91%
2020-03-31 $-0.29B $-0.11B 1933.33%
2019-12-31 $-0.30B $-0.05B -2307.69%
2019-09-30 $-0.29B $0.02B -770.27%
2019-06-30 $-0.28B $0.08B -546.34%
2019-03-31 $-0.27B $0.00B -592.43%
2018-12-31 $-0.25B $0.05B -451.14%
2018-09-30 $-0.22B $0.07B -343.31%
2018-06-30 $-0.18B $0.06B -243.48%
2018-03-31 $-0.14B $0.04B -148.57%
2017-12-31 $-0.12B $0.08B -91.05%
2017-09-30 $-0.08B $0.12B -53.72%
2017-06-30 $-0.09B $0.15B -76.36%
2017-03-31 $-0.08B $0.17B -109.80%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00